ReviewTherapeutic advances in hematology2016

Ofatumumab plus chlorambucil as a first-line therapy in less fit patients with chronic lymphocytic leukemia: analysis of COMPLEMENT1 and other monoclonal antibodies association data.

Anna Maria Frustaci et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.